Get the Stockscreener App
40.97
1.29%
0.52
After Hours:
40.97
Sionna Therapeutics Inc stock is traded at $40.97, with a volume of 321.34K.
It is up +1.29% in the last 24 hours and up +1.19% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$40.45
Open:
$41.53
24h Volume:
321.34K
Relative Volume:
0.92
Market Cap:
$1.85B
Revenue:
-
Net Income/Loss:
$-75.27M
P/E Ratio:
-24.15
EPS:
-1.6963
Net Cash Flow:
$-66.67M
1W Performance:
+3.49%
1M Performance:
+1.19%
6M Performance:
+16.79%
1Y Performance:
+220.33%
1-Day Range:
$40.42
$43.73
1-Week Range:
$36.50
$43.73
52-Week Range:
$11.77
$46.46
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
40.97 | 1.83B | 0 | -75.27M | -66.67M | -1.6963 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Citizens | Mkt Outperform |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
A Look At Sionna Therapeutics (SION) Valuation After Its Strong 1 Year Return And Premium P/B Ratio - Yahoo Finance
Wedbush initiates Sionna Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch - AOL.com
Sionna Therapeutics, Inc. $SION Shares Acquired by Jennison Associates LLC - MarketBeat
Trial of SION-719 as Trikafta add-on therapy in CF is fully enrolled - Cystic Fibrosis News Today
JonesTrading Forecasts Strong Price Appreciation for Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Jones Trading raises Sionna Therapeutics price target on trial progress By Investing.com - Investing.com Canada
EDGAR Filing Documents for 0001628280-26-027501 - SEC.gov
Sionna Therapeutics (NASDAQ: SION) details 2026 virtual meeting, board elections - Stock Titan
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch - The Motley Fool
Sionna Therapeutics Completes Phase 2a Enrollment for SION-719 in Cystic Fibrosis - marketscreener.com
Sionna completes enrollment in cystic fibrosis drug trial By Investing.com - Investing.com Canada
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial for SION-719 in Cystic Fibrosis - Quiver Quantitative
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis - ChartMill
Sionna Therapeutics (SION) Q1 2025 earnings summary - Quartr
Sionna Therapeutics (SION) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Sionna Therapeutics (SION) Cantor Global Healthcare Conference 2025 Summary - Quartr
Sionna Therapeutics (SION) Leerink Global Healthcare Conference 2026 Summary - Quartr
Sionna Therapeutics (SION) Q4 2025 earnings summary - Quartr
Sionna Therapeutics (SION) Q2 2025 earnings summary - Quartr
Sionna Therapeutics (SION) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 11.3%What's Next? - MarketBeat
Sionna Therapeutics Insider Sold Shares Worth $2,472,343, According to a Recent SEC Filing - marketscreener.com
OrbiMed Advisors sells $2.47m in Sionna Therapeutics stock By Investing.com - Investing.com Australia
Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 52,397 Shares - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Director Sells $2,341,097.96 in Stock - MarketBeat
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 2,948 Shares of Stock - MarketBeat
Sionna Therapeutics director Peter A. Thompson sells $2.47m in stock - Investing.com
OrbiMed Advisors sells $2.47m in Sionna Therapeutics stock - Investing.com
Sionna Therapeutics director Peter A. Thompson sells $2.47m in stock By Investing.com - Investing.com India
OrbiMed fund tied to Sionna (NASDAQ: SION) director trims 55K shares - Stock Titan
OrbiMed-backed Sionna (NASDAQ: SION) sees fund share sale - Stock Titan
Why Sionna Therapeutics Stock Is Sinking Now - TipRanks
OrbiMed (SION) cuts Sionna stake to 6.6% after April share sales - Stock Titan
Is Sionna Therapeutics (SION) stock expensive relative to growth (-3.76%) 2026-04-18Weak Sell Rating - Cổng thông tin điện tử tỉnh Tây Ninh
OrbiMed Advisors sells Sionna Therapeutics (SION) stock worth $22.9m By Investing.com - Investing.com UK
Peter Thompson Sells 235,863 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Orbimed Advisors Llc Sells 235,863 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 47,814 Shares - MarketBeat
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 226,906 Shares of Stock - MarketBeat
Sionna Therapeutics (SION) director Thompson sells $22.9 million in stock By Investing.com - Investing.com Canada
Sionna Therapeutics (SION) director Thompson sells $22.9 million in stock - Investing.com
Sionna Therapeutics(SION.US) Director Sells US$22.95 Million in Common Stock - Moomoo
OrbiMed Advisors sells Sionna Therapeutics (SION) stock worth $22.9m - Investing.com
OrbiMed fund linked to Sionna Therapeutics (SION) director sells 510K shares - Stock Titan
OrbiMed entities sell Sionna Therapeutics (SION) stock under 10b5-1 plan - Stock Titan
Operating cash flow per share of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Sionna Therapeutics stock hits all-time high at 45.17 USD By Investing.com - Investing.com Australia
Why Sionna Therapeutics Stock Is Sliding After a Surge - TipRanks
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Sionna Therapeutics Inc Stock (SION) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):